← Back to Screener
Avidity Biosciences, Inc. Common Stock (RNAM)
Price$0.00
Favorite Metrics
Market Capitalization$11.30B
All Metrics
Revenue Growth (3Y)5.31%
Cash Flow / Share (Quarterly)$-4.06
Net Profit Margin (TTM)-2634.59%
EPS (TTM)$-4.17
10-Day Avg Trading Volume16.84M
EPS Excl Extra (TTM)$-4.17
Revenue Growth (5Y)36.26%
EPS (Annual)$-2.89
ROI (Annual)-22.62%
Net Profit Margin (5Y Avg)-1796.59%
Cash / Share (Quarterly)$12.78
Revenue Growth QoQ (YoY)434.03%
ROA (Last FY)-20.61%
Revenue Growth TTM (YoY)106.27%
EBITD / Share (TTM)$-4.65
ROE (5Y Avg)-28.11%
Operating Margin (TTM)-2934.90%
Cash Flow / Share (Annual)$-2.57
P/B Ratio5.99x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-2.35x
ROA (TTM)-33.70%
EPS Incl Extra (Annual)$-2.89
Current Ratio (Annual)15.73x
Quick Ratio (Quarterly)11.48x
3-Month Avg Trading Volume16.84M
Revenue / Employee (TTM)$0
P/S Ratio (Annual)1036.80x
Asset Turnover (Annual)0.01x
52-Week High$73.04
Operating Margin (5Y Avg)-1959.94%
EPS Excl Extra (Annual)$-2.89
CapEx CAGR (5Y)96.69%
Quick Ratio (Annual)15.61x
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.57x
Revenue / Share Growth (5Y)13.23%
Asset Turnover (TTM)0.01x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-2957.71%
Cash / Share (Annual)$12.52
Net Income / Employee (TTM)$-1
ROE (Last FY)-22.62%
EPS Basic Excl Extra (Annual)$-2.89
Receivables Turnover (TTM)19.72x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-4.17
ROI (TTM)-37.70%
P/S Ratio (TTM)541.40x
Pretax Margin (5Y Avg)-1796.59%
Revenue / Share (Annual)$0.10
EPS Normalized (Annual)$-2.89
ROA (5Y Avg)-24.50%
Net Profit Margin (Annual)-2957.71%
EBITD / Share (Annual)$-3.37
Operating Margin (Annual)-3477.43%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-28.11%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.17
Pretax Margin (TTM)-2634.59%
P/FCF (Annual)5021.33x
Revenue / Share (TTM)$0.15
ROE (TTM)-37.70%
52-Week Low$72.75
Analyst Recommendations
Nov 2025
Dec 2025
Jan 2026
Feb 2026
3.76
3.50
3.50
3.50
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RNAMAvidity Biosciences, Inc. Common Stock | 541.40x | 106.27% | — | — | $0.00 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Avidity Biosciences is a biopharmaceutical company developing a novel class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs). The company has three programs in registrational clinical trials: Del-desiran for myotonic dystrophy type 1, Del-zota for Duchenne muscular dystrophy, and Del-brax for facioscapulohumeral muscular dystrophy.